Trocars Market Size Worth $991.1 Million By 2026 | CAGR 4.3%

The global Trocars Market size is estimated to reach USD 991.1 million by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 4.3% during the forecast period. Rising geriatric population, increasing reliance on laparoscopic surgeries, and favorable reimbursement policies in developed countries are some of the primary growth stimulants for the market.

Favorable reimbursement policies by governments and key players for surgical devices and instruments are projected to boost the growth of the market over the forecast period. Key players are providing favorable reimbursement policies in order to promote minimally invasive surgeries, laparoscopic surgeries, and bariatric surgeries. For instance, Ethicon (subsidiary of Johnson & Johnson) conducts Reimbursement Support Program to help healthcare providers with reimbursement related to laparoscopic surgeries and minimally invasive surgeries. These initiatives are most likely to help healthcare providers to take up these procedures instead of traditional ones. Thus, these factors are likely to drive the market over the forecast period.

In addition, the volume of surgeries has increased manifolds due to increasing geriatric population worldwide. Geriatric population are prone to various diseases, which require various surgical interventions for treatment. According to estimates published by WHO, the global elderly population is likely to increase from 841.0 million in 2014 to more than 2.0 billion by 2050.

Request For A Free Consultation@ https://www.grandviewresearch.com/request-free-consultation/5380/rfc

 Trocars Market Report Highlights

• The global disposable trocars market is expected to dominate the market in 2017. Disposable trocars deliver high quality medical output and the chance of post-operative infection is low.
• Optical trocars are anticipated to be the fastest growing segment with a CAGR of over 4.5% owing to increasing demand for technologically advanced devices for surgeries
• Gynaecological surgery represented the largest share in 2017, with a valuation of USD 174.64 million, owing to increasing prevalence of gynaecological disorders across the globe.
• North America dominated the market in 2017 and accounted for approximately half of market revenue. Rising number of surgeries, advancements in healthcare infrastructure, and increasing demand for technologically advanced surgical procedures are contributing to the growth of the region
• Asia Pacific is poised to witness the highest growth in the market due to high population, rising geriatric population, and expanding base of patients with unmet needs
• Some of the key companies present in the market are CONMED Corporation; The Cooper Companies Inc.; Teleflex Incorporated; GENICON, Inc.; Medtronic; B.Braun Medical Inc.; and Johnson & Johnson. 

Related Press Release@ Trocars Market Report

Trocars Market Segmentation                    

Grand View Research has segmented the global trocars market on the basis of product, tip, application, and region:

Trocars Product Outlook (Revenue, USD Million, 2014 - 2026)

• Disposable Trocars
• Reusable Trocars

Trocars Tip Outlook (Revenue, USD Million, 2014 - 2026)

• Bladeless Trocars
• Optical Trocars
• Blunt Trocars
• Bladed Trocars

Trocars Application Outlook (Revenue, USD Million, 2014 - 2026)

• General Surgery
• Gynecological Surgery
• Urological Surgery
• Pediatric Surgery
• Other Surgeries

Trocars Regional Outlook (Revenue, USD Million, 2014 - 2026)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Asia Pacific
• Japan
• China
• Latin America
• Brazil
• Mexico
• MEA
• South Africa
• Saudi Arabia

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Mycoplasma Testing Market By Thermo Fisher Scientific, Inc.; Merck KGaA; Lonza Group AG; Charles River Laboratories International, Inc.

 

The global Mycoplasma Testing Market size is expected to reach USD 2.26 billion by 2030, registering a CAGR of 13.4% over the forecast period, according to a new report by Grand View Research, Inc. The major factors driving the expansion of market includes growing demand for mycoplasma testing in biomanufacturing, emerging economies, and growing pharmaceutical outsourcing. Additionally, the market's overall growth is driven by rising cell-line contamination and innovation & research in biological sciences.

Growing number of government initiatives to support pharmaceutical and biotechnology companies is also driving the market growth. The U.S. FDA proposed to remove a test for detecting mycoplasma within in vitro living cell cultures, as it can help identify only a single test method. These changes in biologics regulations are anticipated to improve specificity and sensitivity in mycoplasma detection tests, leading to introduction of new technologies in the industry. This is expected to create immense opportunities for key players in new product development.

The rates of M. pneumoniae positivity sharply decreased during the COVID-19 pandemic outbreak at the end of 2019. This was a result of the COVID-19 pandemic's stringent regulations, which successfully stopped the spread of M. pneumonia. However, it is anticipated that M. pneumonia will expand even more throughout the research period following the relaxation of COVID-19 limits, which will have a positive impact on the mycoplasma testing market's growth.

Increasing investments in R&D have contributed significantly to the market’s revenue growth. With rising healthcare expenditure, research activities in the life sciences industry are increasing significantly. The adoption of new technologies for drug discovery & development and innovations in cell culture technologies are driving the demand for mycoplasma tests. The high risk of cell culture contamination remains the primary factor expected to drive the mycoplasma testing market over the forecast period

Mycoplasma is estimated to contaminate around 15%-35% of all continuous cell cultures around the world. Out of over 190 known species of mycoplasma, only eight species are responsible for more than 95% of cell culture contamination. Poor cultural practices, aerosols, dust, and cross-contamination as a result of faulty or broken laminar flow are some of the factors responsible for an increase in the number of cell culture contamination events. Such factors are likely to drive the market demand for mycoplasma testing solutions.

List of Key Players of Mycoplasma Testing Market 

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Lonza Group AG
• Charles River Laboratories International, Inc.
• PromoCell GmbH
• American Type Culture Collection
• Asahi Kasei Medical Co., Ltd.
• Sartorius AG
• InvivoGen
• Eurofins Scientific

Related Press Release@ Mycoplasma Testing Market Report

Mycoplasma Testing Market Report Highlights

• By product, kits and reagents dominated the market, and are anticipated to exhibit the fastest CAGR throughout the forecast period, due to their widespread use in mycoplasma testing
• By technology, the polymerase chain reaction segment held a largest share of 32.38% in 2022 which can be attributed to the technology's ability to give quick and precise findings
• Ease of conducting the procedure and rapid detection are some of the major advantages offered by the PCR method
• By application, the cell line testing segment held a largest share of 41.46% in 2022, owing to the increase in research projects being done in the field of cell culture
• Mycoplasma contamination can cause alterations in cell culture metabolites and lead to development of toxins. This increases the importance of cell line testing and authentication in the pharmaceutical and biopharmaceutical industries
• North America held the largest share of 39.08% in 2022. This is mostly attributed to the presence of significant market participants, as well as rising R&D spending and federal assistance 
• In Asia Pacific, the market is expected to grow at the highest rate in a projected time period driven by factors such as the rising prevalence of target diseases with an aging population, rising awareness and others 

Request A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/4232/rfc

Mycoplasma Testing Market Segmentation 

Grand View Research has segmented the global mycoplasma testing market on the basis of product, technology, application, end-use, and region:

Mycoplasma Testing Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments
• Kits & Reagents
•       PCR Assays
•       Nucleic Acid Detection Kits
•       Stains
•       Elimination Kits
•       Standards & Controls
•       Others
• Services

Mycoplasma Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)

• PCR
• ELISA
• Direct Assay
• Indirect Assay
• Microbial Culture Techniques
• Enzymatic Methods

Mycoplasma Testing Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cell Line Testing
• Virus Testing
• End of Production Cells Testing
• Others

Mycoplasma Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others

Mycoplasma Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Spain
• France
• Italy
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• South Korea
• Thailand
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• MEA
• South Africa
• Saudi Arabia
• UAE
• Kuwait

About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Multiplex Assay Market Size is Predicted to Witness 14.77% CAGR till 2030

 

The global Multiplex Assay Market size is expected to reach USD 3.87 billion by 2030, registering a CAGR of 14.77% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of infectious diseases is boosting the usage of multiplex assays in clinical trials. For instance, according to the American Cancer Society in 2021, 1.9 million cancer cases were reported along with 6,08,570 deaths in the United States. Multiplex assay aids in the diagnosis of cancer and reduces unnecessary invasive producers. Thus, growing chronic diseases can boost the necessity of these assays and is anticipated to fuel market growth. The increasing adoption of personalized medicine in recent years is another key factor driving the growth.

Personalized medicine is a precise medicine for an individual patient to attain improved treatment options based on the body type and disease risk. These assays ensure to be highly beneficial for the comprehensive diagnosis of personalized medicines. For instance, according to an article published in the MDPI journal in 2020, multiplex immunoassay provides a complete picture of the disease and pathways involved in Rheumatoid Arthritis (RA) and simultaneously analyzes multiple proteins that can yield biomarker signatures of RA subtypes to enable patients to benefit from personalized medicine. During the COVID-19 pandemic, multiplex testing continued to be an essential tool for healthcare professionals in effectively managing the spread of COVID-19. In addition, recently, several private companies have also developed novel versions of multiplex assays.

For instance, in Sept 2020, LabCorp launched an at-home collection version for diagnosis of influenza A/B, COVID-19, and respiratory syncytial virus single-panel tests. Furthermore, the advantages of multiplex assay over singleplex and traditional assay can boost the industry growth in coming years. Several benefits offered by these automated tests include microsampling capability, numerous arrays measured in a single trial, quicker results, high operational efficiency, easy operations, and reduced labor expenses. Thus, the industry has witnessed incremental growth in 2021 and is anticipated to have a similar trend during the forecast period. Moreover, increasing validation of the biomarkers in molecular & protein diagnostics and the rising need for high-throughput and automated systems are expected to create lucrative opportunities during the forecast period.

Multiple biomarker analysis has a wide range of applications in the area of infectious diseases, neurodegenerative diseases, autoimmune diseases, and cancer. Numerous biomarkers are being discovered, and there is a high possibility of the development of novel diagnostics. For instance, Cipla launched RT Direct multiplex PCR kit that delivers quicker results for COVID-19. Such developments can increase the market penetration of multiplex assay during the forecast period. The technological advancements and automation in the multiplex assay, improve the efficiency and speed of delivering accurate results. For instance, in July 2020, Luminex provided xMAP the INTELLIFLEX system to discover novel applications, including the exclusive ability to detect multiple antibodies in a single serology test.

In May 2022, Vela Diagnostics launched a highly automated multiplex PCR-based test for detecting antimicrobial resistance genes and UTI pathogens. Hence novel technological developments can fuel the industry growth in the near future. However, the high cost of equipment can restrict the usage of multiplex assays by researchers and manufacturers in mid and low-income countries. Also, the quality control standards and regulations are more stringent for multiplex assay compared to singlex assay, which can impede the industry growth during the forecast period.

Related Press Release@ Multiplex Assay Market Report

Multiplex Assay Market Report Highlights

• By product, the consumables segment held the dominant share in 2022. This is due to the recurring purchase of consumables along with the rise in the number of diagnostic tests
• The protein multiplex assay type segment dominated the industry in 2022 due to the increasing focus on proteomics studies for biomarker research and clinical diagnostics
• The flow cytometry technology segment held a larger share in 2022. Constant efforts by various companies to launch novel and technological advanced flow cytometer is the key factor driving the segment
• The research & development application segment held the largest share in 2022 due to the utilization of these assays in clinical & preclinical stages to evaluate toxicity, immunotherapy success, and drug response biomarkers
• The pharmaceutical & biotechnology companies end-user segment led the industry in 2022 due to a rise in pharma & biotech partnerships and collaborations to increase the multiplexing capabilities
• North America dominated the global industry in 2022 due to the growing R&D activities as a result of the increasing prevalence of chronic diseases
• Asia Pacific is estimated to register the fastest CAGRfrom 2022 to 2030 due to the rising number of hospitals in emerging countries, the developing R&D sector, and the high demand for healthcare infrastructure in the region

Multiplex Assay Market Segmentation

Grand View Research has segmented the global multiplex assay market based on product, type, technology, application, end-user, and region:

Multiplex Assay Product Outlook (Revenue, USD Million, 2018 - 2030)

• Consumables
• Instruments
• Software

Multiplex Assay Type Outlook (Revenue, USD Million, 2018 - 2030)

• Protein Multiplex Assays
• Planar Protein Assays
• Bead-based Protein Assays
• Nucleic Acid Multiplex Assays
• Planar Protein Assays
• Bead-based Protein Assays
• Cell-based Multiplex Assays

Multiplex Assay Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Flow Cytometry
• Fluorescence Detection
• Luminescence
• Multiplex Real-time PCR
• Other Technologies

Multiplex Assay Application Outlook (Revenue, USD Million, 2018 - 2030)

• Research & Development
• Drug Discovery & Development
• Biomarker Discovery & Validation
• Clinical Diagnostics
• Infectious Diseases
• Cancer
• Cardiovascular Diseases
• Autoimmune Diseases
• Nervous System Disorders
• Metabolism & Endocrinology Disorders
• Other Diseases

Multiplex Assay End-user Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostic laboratories
• Research & Academic Institutes
• Other End-users

Multiplex Assay Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Asia Pacific
• Japan
• China
• India
• South Korea
• Australia
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

List of Key Players in Multiplex Assay Market

• Luminex Corp.
• Bio-Rad Laboratories, Inc.
• Abcam plc.
• Seegene Inc.
• Merck KGaA
• Assay Genie
• Promega Connections
• QIAGEN N.V.
• Thermo Fisher Scientific
• Perkin Elmer Inc.
• Advanced Cell Diagnostics, Inc.
• R&D Systems, Inc.

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com

Wheat Protein Market – Industry Insights By Product And Application

 

The global Wheat Protein Market size is expected to reach USD 9.28 billion by 2030, expanding at a CAGR of 4.5% from 2022 to 2030, according to a new report by Grand View Research, Inc. Growing consumer preference for meat-free diets globally, and increasing product applications in various end-use industries, are the major factors driving the market growth. Furthermore, increasing cases of lactose intolerance have increased the demand for whey protein.

The demand for food products that promote better health, particularly those that are low in fat and cholesterol, high in protein, and useful for weight management, has increased owing to rising consumers' health awareness. The number of food products that contain plant-based protein has consequently increased significantly over the past few years. Furthermore, the increasing popularity of trends such as all-natural and clean-label products is anticipated to boost demand for wheat protein.

Wheat protein is widely used in the food and beverage industry, mainly in nutritional supplements, sports foods, dairy products, confectioneries, and baked goods, among other applications. Two insoluble protein groups that can be found in wheat protein are glutenin and gliadin. It is used in the manufacturing of noodles and bread as wheat protein permits a high level of dough strength by creating an elastic texture. The use of these products in the food and cosmetic industries is expected to increase due to changing consumer perceptions of wheat proteins and FDA approval for use in food products during the estimated period.

The small intestine is damaged by gluten intolerance or celiac disease, an autoimmune condition that prevents the body from absorbing nutrients from food. This harm is primarily a response to eating foods containing gluten, a form of wheat protein also found in barley, oats, and rye. However, some people may still feel uncomfortable in their stomachs even though they do not suffer from Celiac disease. This factor might limit market expansion in the coming years.

Europe is anticipated to grow at a substantial CAGR from 2022 to 2030 due to an increase in the consumption of healthy food products. France is experiencing stable growth on account of hectic work and changing lifestyles leading to increased consumption of functional food & beverages in the country. The regional growth can also be attributed to the rising demand for high-quality French bakery items. Baked product manufacturers in the region prefer wheat protein as an alternative to animal and dairy proteins while developing new products which will fuel product demand.

Related Press Release@ Wheat Protein Market Report

Wheat Protein Market Report Highlights

• Wheat gluten held the largest market share in 2021 owing to its ease of availability, binding properties, and high mineral and protein content
• 75% protein concentration held the highest revenue share in 2021 due to its high concentration of diluted protein
• Personal Care in the application segment is expected to expand at a significant CAGR from 2022 to 2030, attributed to rising consumer demand for herbal and organic cosmetics
• Asia Pacific is estimated to grow significantly over the forecast period owing to various developments in healthcare and cosmetic sectors in developing countries in the region

Wheat Protein Market Segmentation

Grand View Research has segmented the global wheat protein market based on product, protein concentration, application, and region:

Product Outlook (Volume, Kilotons; Revenue, USD Million, 2017 - 2030)

• Wheat Gluten
• Wheat Protein Isolates
• Textured Wheat Proteins
• Wheat Protein Hydrolysates

Concentration Outlook (Volume, Kilotons; Revenue, USD Million, 2017 - 2030)

• 75% concentration
• 80% concentration
• 95% concentration

Application Outlook (Volume, Kilotons; Revenue, USD Million, 2017 - 2030)

• Bakery & Confectionaries
• Animal Feed
• Dairy
• Personal Care
• Sports & Nutrition

Regional Outlook (Volume, Kilotons; Revenue, USD Million, 2017 - 2030)

• North America

• U.S.
• Canada
• Mexico
• Europe
• Russia
• Ukraine
• France
• Germany
• Poland
• Asia Pacific
• China
• India
• Australia
• Central & South America
• Brazil
• Argentina
• Middle East & Africa
• Turkey
• Egypt

List of Key Players in the Wheat Protein Market

• Archer Daniels Midland Company (ADM)
• Agridient
• MGP Ingredients
• AB Amilina
• Cargill Inc
• Manildra Group
• Crespel & Deiters GmbH and Co. KG
• Kroener Staerke
• Crop Energies AG
• Roquette

 About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com